Trials / Completed
CompletedNCT03333057
Perfluorohexyloctane (NOV03) for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)
A Phase 2, Multi-Center, Randomized, Double-Masked, Saline-Controlled Study to Evaluate the Effect of Perfluorohexyloctane (NOV03) at Two Different Dosing Regimens on Signs and Symptoms of Dry Eye Disease (DED)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 336 (actual)
- Sponsor
- Novaliq GmbH · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the efficacy, safety and tolerability of perfluorohexyloctane (NOV03) at two different dosing regimens compared to saline solution in subjects with Dry Eye Disease (DED).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | NOV03 | Perfluorohexyloctane |
| DRUG | Placebo | Saline solution (0.9% sodium chloride solution) |
Timeline
- Start date
- 2018-01-03
- Primary completion
- 2018-05-18
- Completion
- 2018-07-27
- First posted
- 2017-11-06
- Last updated
- 2022-01-04
- Results posted
- 2021-05-24
Locations
11 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03333057. Inclusion in this directory is not an endorsement.